Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cardiology and Therapy
Published in: Cardiology and Therapy 1/2013

Open Access 01-06-2013 | Case Report

Fenestrated Atrial Septal Defect Percutaneously Occluded by a Single Device: Procedural and Financial Considerations

Authors: Roie Tal, Qarawani Dahud, Avraham Lorber

Published in: Cardiology and Therapy | Issue 1/2013

Login to get access

Abstract

A 45-year-old patient presented with a cerebrovascular attack and was subsequently found to have a multi-fenestrated atrial septal defect. Various therapeutic options for percutaneous transcatheter closure with their respective benefits and flaws are discussed, as well as procedural and financial considerations. The decision making process leading to a successful result using a single occlusive device is presented, alongside a review of the literature.
Literature
1.
Rigby ML. Atrial septal defect. In: Gatzoulis MA, Webb GD, Daubeney PEF, editors. Diagnosis and management of adult congenital heart disease. 1st ed. Spain: Churchill Livingstone; 2003. p. 163–70.
2.
Du ZD, Hijazi ZM, Kleinman CS, Silverman NH, Aplatzer investigators. Comparison between transcatheter and surgical closure of secundum atrial septal defect in children and adults: results of a multicenter nonrandomized trial. J Am Coll Cardiol. 2002;39:1836–44.PubMedCrossRef
3.
Podnar T, Martanovic P, Gavora P, Masura J. Morphological variations of secundum-type atrial septal defects: feasibility for percutaneous closure using Amplatzer septal occluders. Catheter Cardiovasc Interv. 2001;53:386–91.PubMedCrossRef
4.
Buerta G, Biondi-Zoccai G, Sangiorgi G, et al. Percutaneous versus surgical closure of secundum atrial septal defects: a systematic review and meta-analysis of currently available clinical evidence. EuroIntervention. 2011;7:377–85.CrossRef
5.
King TD, Thompson SL, Steiner C, Mills NL. Secundum atrial septal defect. Nonoperative closure during cardiac catheterization. JAMA. 1976;235:2506–9.PubMedCrossRef
6.
Awad SM, Garay FF, Cao QL, Hijazi ZM. Multiple Amplatzer septal occluder devices for multiple atrial communications: immediate and long-term follow-up results. Catheter Cardiovasc Interv. 2007;70:265–73.PubMedCrossRef
7.
Zanchetta M, Rigatelli G, Pedon L, Zennaro M, Carrozza A, Onorato E. Catheter closure of perforated secundum atrial septal defect under intracardiac echocardiographic guidance using a single amplatzer device: feasibility of a new method. J Invasive Cardiol. 2005;17:262–5.PubMed
8.
Tillman T, Mulingtapang R, Sullebarger JT. Approach to percutaneous closure in patients with multiple atrial septal defects. J Invasive Cardiol. 2008;20:E167–70.PubMed
9.
Butera G, Romagnoli E, Saliba Z, et al. Percutaneous closure of multiple defects of the atrial septum: procedural results and long-term follow-up. Catheter Cardiovasc Interv. 2010;76:121–8.PubMedCrossRef
10.
Carano N, Hagler DJ, Agnetti A, Squarcia U. Device closure of fenestrated atrial septal defects: use of a single Amplatz atrial septal occluder after balloon atrial septostomy to create a single defect. Catheter Cardiovasc Interv. 2001;52:203–7.PubMedCrossRef
11.
Szkutnik M, Masura J, Bialikowski J, et al. Transcatheter closure of double atrial septal defects with a single Amplatzer device. Catheter Cardiovasc Interv. 2004;61:237–41.PubMedCrossRef
12.
Numan M, El Sisi A, Tofeig M, Gendi S, Tohami T, El-Said HG. Cribriform Amplatzer device closure of fenestrated atrial septal defects: feasibility and technical aspects. Pediatr Cardiol. 2008;29:530–5.PubMedCrossRef
13.
Masseli J, Bertog S, Stanczak L, et al. Transcatheter closure of multiple interatrial communications. Catheter Cardiovasc Interv. 2012 (Epub ahead of print).
Metadata
Title
Fenestrated Atrial Septal Defect Percutaneously Occluded by a Single Device: Procedural and Financial Considerations
Authors
Roie Tal
Qarawani Dahud
Avraham Lorber
Publication date
01-06-2013
Publisher
Springer Healthcare
Published in
Cardiology and Therapy / Issue 1/2013
Print ISSN: 2193-8261
Electronic ISSN: 2193-6544
DOI
https://doi.org/10.1007/s40119-012-0009-5

Other articles of this Issue 1/2013

Cardiology and Therapy 1/2013 Go to the issue

Review

Thrombin Receptor Antagonism in Antiplatelet Therapy

Review

Current and Emerging Antiarrhythmic Drug Therapy for Ventricular Tachycardia

Review

Glycemic Control: A Combination of Lifestyle Management and the Use of Drugs

Case Report

Dabigatran Excess: Case Report and Review of the Literature

Review

The Resolute™ Integrity Zotarolimus-Eluting Stent in Coronary Artery Disease: A Review

Review

Optimal Choice of Coronary Revascularization and Stent Type in Diabetic Patients with Coronary Artery Disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits